Modus Therapeutics Holding AB operates as a biotechnology company. It develops sevuparin with a focus on diseases with a high unmet medical need. The firm focuses to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company